These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18748016)

  • 1. Neurology-epitomes of progress: carbidopa-levodopa combination in treatment of Parkinson disease.
    Bounds JA; Hunt GM
    West J Med; 1977 Aug; 127(2):135-6. PubMed ID: 18748016
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
    Mao ZL; Modi NB
    J Clin Pharmacol; 2016 Aug; 56(8):974-82. PubMed ID: 26632091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
    Rahman MM; Uddin MJ; Chowdhury JH; Chowdhury TI
    Mymensingh Med J; 2014 Jan; 23(1):18-23. PubMed ID: 24584367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease].
    Rudakova AV; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
    Buhmann C; Hilker R; Lingor P; Schrader C; Schwarz J; Wolz M; Reichmann H
    J Neural Transm (Vienna); 2017 Aug; 124(8):1005-1013. PubMed ID: 28229223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
    Gilligan B; Wodak J; Stark R; O'Halloran M
    Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
    Langdon N; Malcolm PN; Parkes JD
    Clin Neuropharmacol; 1986; 9(5):440-7. PubMed ID: 3768866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
    Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
    Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
    Hoehn MM
    Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
    Tourtellotte WW; Syndulko K; Potvin AR; Hirsch SB; Potvin JH
    Arch Neurol; 1980 Nov; 37(11):723-6. PubMed ID: 7436817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
    Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.